Addiction is a chronic condition, not a single event, and treatment works best when care stays consistent over months, not weeks. For many people with opioid use disorder, though, consistent care is hard to reach. Clinics sit far from home. Appointments clash with work shifts. Stigma keeps people from walking through a waiting room door. Telemedicine for addiction treatment removes several of these barriers at once, connecting patients to assessments, counseling, and medication management from wherever they already are.
The approach has moved well past pandemic-era convenience. Telehealth platforms built for addiction treatment now handle initial diagnostic evaluations, individual and group therapy, and ongoing medication consultations for treatments such as buprenorphine. Research on how these programs perform, compared with traditional entry points like the emergency department, has also matured. A study published in the Journal of Substance Use and Addiction Treatment gives one of the clearest pictures yet of what telemedicine for addiction treatment can do for engagement and retention.
Why Telemedicine for Addiction Treatment Outperforms the Emergency Department
Researchers from the University at Buffalo studied 1,349 referrals made through the Medication for Addiction Treatment and Electronic Referrals (MATTERS) Network between October 2020 and September 2022, publishing their findings in the Journal of Substance Use and Addiction Treatment. Nearly half, 47.8%, of referrals came through telemedicine. Nearly 40%, 39.7%, came from emergency department visits. The two paths led to very different outcomes.
- 65.1% of patients referred through telemedicine attended their first clinic appointment, compared with 32.3% of patients referred from the emergency department.
- 53.2% of telemedicine patients were still in treatment at 30 days, compared with 22.2% of patients referred from the emergency department.
- Patients referred through telemedicine were 1.64 times more likely to attend an initial appointment and 2.59 times more likely to remain engaged in care at 30 days.
These are not small margins. An emergency department visit is often the only contact a person in crisis has with the health system, and it is a narrow window to start lasting treatment. Telemedicine for addiction treatment gives that same person a lower-friction way to keep the appointment that follows, and then the one after that.
New Evidence Beyond the Emergency Department
A separate body of research, built on the HEALing Communities Study, the largest addiction-prevention implementation effort conducted to date, adds more weight to these findings. Investigators reviewed Medicaid claims from Kentucky and Ohio covering nearly 43,000 people who started buprenorphine treatment in 2020, with a focused look at 9,172 patients in Kentucky and 12,328 in Ohio who began treatment when telehealth flexibilities were most available.
In Kentucky, 48% of patients who started buprenorphine through telehealth stayed in treatment for 90 continuous days, compared with 44% of patients who started in person. In Ohio, the gap ran 32% to 28% in telehealth’s favor. Telehealth initiation also showed no association with a higher risk of nonfatal overdose, which speaks directly to a common worry about treating opioid use disorder remotely.
The same research flagged a real gap worth naming honestly. Non-Hispanic Black patients, men, and patients with a prior overdose were less likely to access or stay in telehealth-delivered care. Expanding telemedicine for addiction treatment only helps as much as it reaches the people who need it, and closing that access gap is unfinished work for the field.
The 2026 Rules Behind Telemedicine for Addiction Treatment
Access to telemedicine for addiction treatment has depended, in part, on a regulatory exception that keeps getting renewed rather than made permanent. Federal law generally requires an in-person medical evaluation before a practitioner can prescribe a controlled substance, and buprenorphine falls under that rule. Since the COVID-19 public health emergency, the DEA and HHS have repeatedly extended a flexibility that allows Schedule III-V medications approved for opioid use disorder treatment, including buprenorphine, to be prescribed through audio-only telemedicine without that in-person visit.
The fourth such extension runs through December 31, 2026. Prescriptions still have to meet standing requirements: a legitimate medical purpose, an interactive telecommunications system, and a properly registered, licensed practitioner. Regulators have been explicit about why they keep renewing rather than letting the flexibility lapse. When a related Medicare telehealth flexibility briefly expired in 2025, fee-for-service telehealth visits fell 24% within 17 days, and by nearly 40% in some states. Agencies now describe the risk of a hard stop as a “telemedicine cliff,” language that signals how much ongoing access has come to rely on these rules staying in place.
For care teams and patients, the practical takeaway is that telemedicine for addiction treatment remains available through 2026, but on a renewal cycle rather than a permanent footing. Practices that rely on it should track the rule’s status rather than assume it.
The Benefits of Telemedicine for Addiction Treatment
Three advantages show up again and again across this research: less stigma, care delivered at home, and shorter waits to be seen. Each one addresses a specific reason people delay or avoid addiction treatment.
Stigma keeps some patients from ever walking into a clinic that treats substance use. A video visit from a private room removes that exposure. Home-based delivery matters just as much for people managing transportation costs, childcare, or a job that does not allow for a half-day absence. And shorter waiting times mean a person who has decided, today, to seek help does not lose that window to a scheduling backlog.
These same barriers weigh heaviest in areas with the fewest specialists nearby. Rural communities often travel the farthest for addiction care, and telemedicine narrows that distance to the length of an internet connection. Medication adherence follows a similar pattern: patients who engage consistently with telehealth tend to stick with prescribed regimens more closely than those managing care entirely on their own, a pattern that matters as much for buprenorphine as it does for any other long-term medication.
How Addiction Telehealth Fits Into Broader Remote Care
Telemedicine for addiction treatment does not operate in isolation from the rest of behavioral health. Remote monitoring tools built for behavioral health conditions increasingly work alongside telehealth visits, giving care teams a way to track how a patient is doing between appointments rather than only during them. The same infrastructure that supports remote patient monitoring (RPM) for chronic conditions such as hypertension or diabetes can extend to behavioral health programs that need regular, structured check-ins.
For providers already running RPM or remote therapeutic monitoring (RTM) programs, adding addiction-focused telehealth is less a new system and more an extension of one already in place. That overlap is worth considering for any practice weighing how to reach patients with opioid use disorder without building a separate technology stack from scratch. Opioid use disorder treatment paired with newer RPM technologies is one place this is already happening.
Frequently Asked Questions About Telemedicine for Addiction Treatment
These questions come up often when care teams and patients consider telemedicine for addiction treatment for the first time, from how it works day to day to whether it holds up as well as in-person care.
1) What is telemedicine for addiction treatment?
Telemedicine for addiction treatment uses video or audio visits to deliver diagnostic assessments, individual and group counseling, and medication management for conditions such as opioid use disorder. Patients connect with licensed providers remotely instead of, or in addition to, visiting a clinic in person.
2) How effective is telemedicine for addiction treatment compared with in-person care?
Research through the MATTERS Network found telemedicine-referred patients were 1.64 times more likely to attend their first appointment and 2.59 times more likely to remain in treatment at 30 days than patients referred from the emergency department. Medicaid data from Kentucky and Ohio found similar or better 90-day retention for patients who started buprenorphine through telehealth.
3) Can buprenorphine still be prescribed through telemedicine in 2026?
Yes. The DEA and HHS have extended flexibilities allowing audio-only telemedicine prescribing of buprenorphine and other Schedule III-V medications for opioid use disorder through December 31, 2026. Practitioners must still meet standard requirements, including a legitimate medical purpose and proper registration.
4) Is telemedicine safe for people being treated for opioid use disorder?
Available research has not found an association between telehealth initiation of buprenorphine and higher rates of nonfatal overdose. Safety monitoring remains part of any well-run program, in person or remote.
5) Who benefits most from telemedicine for addiction treatment?
People facing long travel distances, inflexible work schedules, or stigma around visiting an addiction treatment clinic tend to see the clearest gains. Research also shows access is not yet equal. Non-Hispanic Black patients, men, and patients with a prior overdose have been less likely to access or remain in telehealth-delivered care, a gap that ongoing outreach needs to address.
6) What technology does telemedicine for addiction treatment typically require?
Most programs need only a smartphone, tablet, or computer with a camera, a stable internet or phone connection, and a private space for the visit. Some practices pair these visits with remote monitoring tools for patients managing co-occurring chronic conditions.
Understanding Telemedicine for Addiction Treatment
Telemedicine for addiction treatment has moved from a pandemic workaround to a documented, evidence-backed way to help people start and stay in opioid use disorder care. Compared with emergency department referrals, it more than doubles the share of patients who make it to a first appointment and remain in treatment at 30 days. Newer Medicaid data from Kentucky and Ohio points the same direction, without the added overdose risk some providers worried about. None of it depends on a permanent rule yet. Current DEA and HHS flexibilities keep buprenorphine prescribing available through telehealth only through the end of 2026, which makes this a moment for practices to use the access they have rather than assume it will always be there.
Tenovi builds the cellular and Bluetooth-connected device infrastructure that helps care teams monitor patients between visits, whether that means a blood pressure cuff for a hypertension program or tools that support behavioral health and medication-assisted treatment. If your practice is exploring how remote monitoring could work alongside telemedicine for addiction treatment or other chronic care programs, schedule a free demo and consultation with our team.
